BRIEF-FDA Accepts Agios' Supplemental New Drug Application For Pyrukynd® (Mitapivat)
ReutersJan 8, 2025 12:04 PM
Jan 8 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:
FDA ACCEPTS AGIOS’ SUPPLEMENTAL NEW DRUG APPLICATION FOR PYRUKYND® (MITAPIVAT) IN ADULT PATIENTS WITH NON-TRANSFUSION-DEPENDENT AND TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
AGIOS PHARMACEUTICALS INC - PDUFA GOAL DATE FOR PYRUKYND SNDA IS SEPTEMBER 7, 2025
Source text: ID:nGNX5SDZYJ
Further company coverage: AGIO.O
((Reuters.Brief@thomsonreuters.com))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
What Should Stock Investors Watch in Friday’s US Jobs Report?
TradingKey - At this point in time, the stock market is obsessing over how much the US Federal Reserve (Fed) will cut interest rates in 2025.TradingKey
an hour ago
Nvidia CEO’s Remarks Hit Quantum Computing Stocks
TradingKey - Nvidia CEO Jensen Huang’s remarks on Wednesday about the technology hit stocks in the quantum computing sector. He predicted it could take decades for the technology to see widespread adoption, leading to declines in the shares of IonQ, Rigetti Computing, D-Wave Quantum, and Quantum ComTradingKey
4 hours ago
Why Did The S&P 500 And Nasdaq Composite Just Fall Over 1%?
TradingKey - The year 2025 started off on a pretty solid footing for investors with the key indices in the US – the S&P 500 Index and the tech-focused Nasdaq Composite Index – both posting gains in the first few days of trading. That followed on from some huge double-digit gains for 2023 and 2024.TradingKey
Wed, Jan 8
